Delivery and formulation of engineered nucleic acids
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
1. A pharmaceutical composition, comprising:
a modified messenger RNA (mRNA) encoding a polypeptide of interest, wherein the modified mRNA comprises one or more uridines and one or more cytidines and wherein substantially all uridines are modified, and
the modified mRNA is in a lipid nanoparticle formulation comprising a lipid selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, DLin-MC3-DMA, 98N12-5, and C12-200; a cholesterol; and a PEG-lipid.
2. The pharmaceutical composition of claim 1 , wherein the modified uridine is a pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy uridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, or pseudouridine.
3. The pharmaceutical composition of claim 1 , wherein the one or more uridines are modified on the major groove face of the uridine.
4. The pharmaceutical composition of claim 1 , wherein the modified uridine is pseudouridine or 1-methyl-pseudouridine.
5. The pharmaceutical composition of claim 4 , wherein the modified uridine is 1-methyl-pseudouridine.
6. The pharmaceutical composition of claim 2 , wherein the modified mRNA further comprises one or more modified cytidines.
7. The pharmaceutical composition of claim 6 , wherein the modified cytidine is 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 5-methyl-cytidine, or 4-methoxy-1-methyl-pseudoisocytidine.
8. The pharmaceutical composition of claim 7 , wherein the modified cytidine is 5-methyl-cytidine.
9. The pharmaceutical composition of claim 7 , wherein at least about 95% of the uridines are modified and at least about 95% of the cytidines are modified.
10. The pharmaceutical composition of claim 7 , wherein about 100% of the uridines are modified and about 100% of the cytidines are modified.
11. The pharmaceutical composition of claim 1 , wherein the modified mRNA comprises a 5′ Cap1 structure and a polyA tail of 160 nucleotides in length.
12. The pharmaceutical composition of claim 1 , wherein the modified mRNA and lipid nanoparticle are formulated at a total lipid to mRNA weight ratio of 10:1, 15:1, 20:1, or 30:1.
13. The pharmaceutical composition of claim 1 , wherein the lipid is DLin-KC2-DMA or 98N12-5.
14. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle formulation comprises about 42% lipid, about 48% cholesterol, and about 10% PEG-lipid.
15. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle formulation comprises about 50% lipid, about 38.5% cholesterol, and about 1.5% PEG-lipid.
16. The pharmaceutical composition of claim 1 , wherein the modified mRNA further comprises an operably-linked signal sequence, wherein the signal sequence is that of either (i) the polypeptide of interest or (ii) a heterologous protein.
17. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle has a mean particle size between 86 nm and 155 nm.
18. The pharmaceutical composition of claim 1 , wherein the lipid nanoparticle has a polydisperity index between 0.02 and 0.17.
19. The pharmaceutical composition of claim 1 further comprising a formulation buffer for in vivo delivery, wherein the formulation buffer has a pH of 6.5 and comprises sodium chloride, calcium chloride, and Na+-phosphate.
20. The pharmaceutical composition of claim 19 , wherein the formulation buffer comprises 150 mM sodium chloride, 2 mM calcium chloride, and 2 mM Na+-phosphate.